Wuxi PharmaTech closing in on $3.3b take-private

The deal would be the second-largest privatisation of a US-listed Chinese company and could pave the way for a relisting in China or Hong Kong if completed.

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition

CONFERENCES